Breaking News Instant updates and real-time market news.

REPH

Recro Pharma

$7.92

0.38 (5.04%)

07:18
12/10/18
12/10
07:18
12/10/18
07:18

Recro Pharma presents results from meloxicam IV study at PGA72

Recro Pharma announced a poster presentation highlighting intravenous, or IV, meloxicam's effect on platelet function at the PostGraduate Assembly in Anesthesiology, or PGA72. The poster describes results from an ex vivo study assessing the effects of various concentrations of IV meloxicam on platelet function compared to ketorolac and an untreated control. The 5mcg/mL concentration of IV meloxicam in this study corresponds to the maximum plasma levels following a 30mg dose in the clinical setting. Similarly, the 5mcg/mL concentration of ketorolac in this study corresponds to a 30mg and the 2.5mcg/mL dose corresponds to the 15mg dose in the clinical setting. In this study, blood samples provided by healthy volunteers were analyzed to determine closure time, or CT, following the addition of IV meloxicam and ketorolac at the previously mentioned concentrations to the blood plasma samples. The researchers conducted the analyses using a platelet function analyzer, a standard of care for platelet function testing, or CEPI, and two different reagents, collagen with epinephrine and collagen with adenosine diphosphate, or CADP. In the CEPI reagent analysis, a significant treatment effect was observed for changes in CT. No significant difference was observed in CT for the IV meloxicam treated samples versus the untreated control at any of the evaluated concentrations. When compared to untreated control, the ketorolac treated sample CT values were significantly prolonged in both the 2.5mcg/mL and the 5mcg/mL concentrations. All IV meloxicam concentration levels had a significantly shorter CT compared to the 2.5mcg/mL ketorolac concentration. All IV meloxicam concentration levels had numerically shorter CTs compared to the 5mcg/mL ketorolac concentration, though only the 10mcg/mL IV meloxicam concentration reached statistical significance. In the CADP reagent analysis, neither IV meloxicam nor ketorolac demonstrated a significant change in CT versus untreated control.

REPH Recro Pharma
$7.92

0.38 (5.04%)

05/25/18
ROTH
05/25/18
NO CHANGE
Target $8.5
ROTH
Buy
Roth Capital says Recro Pharma manufacturing alone worth more than current price
Roth Capital analyst Scott Henry estimates Recro Pharma's manufacturing business, net of debt, is valued at $8.50 per share, which he noted remains well above the current share price after the stock declined about 55% following the CRL for IV meloxicam. While Henry is not counting on a future for IV meloxicam within his current valuation, he says such a scenario could present material upside. Henry lowered his price target on Recro shares to $8.50 from $18.00 and maintains a Buy rating on the stock, which closed yesterday at $5.63.
05/24/18
PIPR
05/24/18
NO CHANGE
Target $9
PIPR
Overweight
Recro Pharma price target lowered to $9 after 'baffling' CRL at Piper Jaffray
Piper Jaffray analyst David Amsellem lowered his price target on Recro Pharma shares to $9 from $17 after the company received a "cryptic and baffling" complete response letter regarding its NDA for the intravenous form of meloxicam for post-operative pain. Amsellem called the CRL "particularly vexing" given that meloxicam in oral form has been available since 2000 and the IV form was statistically superior to placebo on primary and secondary endpoints in two large Phase 3 studies, making him question if this is "a case of the FDA shifting the goalposts." The analyst, who still believes the product has a commercial future and thinks cash flows from Recro's Gainesville manufacturing facility should provide downside protection, keeps an Overweight rating on the stock, which has plunged over 57% to $5.26.
05/24/18
JANY
05/24/18
NO CHANGE
Target $11
JANY
Buy
Recro Pharma price target lowered to $11 after CRL at Janney Capital
Janney Capital analyst Ken Trbovich lowered his fair value estimate for Recro Pharma shares to $11 from $21 after the company received a Complete Response Letter from the FDA for IV meloxicam. However, Trbovich maintains a Buy rating on Recro Pharma.
04/19/18
BREN
04/19/18
INITIATION
Target $21.25
BREN
Buy
Recro Pharma initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Recro Pharma with a Buy and $21.25 price target.

TODAY'S FREE FLY STORIES

03:40
11/14/19
11/14
03:40
11/14/19
03:40
General news
FX Action: USD-CAD is amid a third consecutive week of ascent »

FX Action: USD-CAD is…

02:55
11/14/19
11/14
02:55
11/14/19
02:55
General news
FX Update: Both the dollar and yen have continued to hold firm »

FX Update: Both the…

01:50
11/14/19
11/14
01:50
11/14/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

01:30
11/14/19
11/14
01:30
11/14/19
01:30
General news
China data misses highlight downside risks »

China data misses…

KDMN

Kadmon

$3.56

-0.155 (-4.18%)

20:59
11/13/19
11/13
20:59
11/13/19
20:59
Syndicate
Kadmon 26M share Spot Secondary priced at $3.40 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

UBER

Uber

$26.70

(0.00%)

20:17
11/13/19
11/13
20:17
11/13/19
20:17
Hot Stocks
Uber chairman buys 35K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

ALPN

Alpine Immune Sciences

$2.49

-0.06 (-2.35%)

19:47
11/13/19
11/13
19:47
11/13/19
19:47
Recommendations
Alpine Immune Sciences analyst commentary at Piper Jaffray »

Alpine Immune Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

19:45
11/13/19
11/13
19:45
11/13/19
19:45
Hot Stocks
HP Inc. raises quarterly dividend to 17.6c from 16.0c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

RETA

Reata Pharmaceuticals

$187.00

4.48 (2.45%)

19:18
11/13/19
11/13
19:18
11/13/19
19:18
Syndicate
Reata Pharmaceuticals 2.4M share Secondary priced at $183.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

BCRX

BioCryst

$1.60

-0.185 (-10.39%)

19:13
11/13/19
11/13
19:13
11/13/19
19:13
Syndicate
BioCryst 37.93M share Secondary priced at $1.45 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

19:03
11/13/19
11/13
19:03
11/13/19
19:03
Periodicals
U.S. lawmaker frustrated with Google's bid to buy Fitbit, Reuters says »

U.S. Representative David…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

FB

Facebook

$193.20

-1.27 (-0.65%)

AMZN

Amazon.com

$1,753.84

-24.49 (-1.38%)

AAPL

Apple

$264.52

2.63 (1.00%)

FIT

Fitbit

$6.86

-0.105 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

PING

Ping Identity

$16.50

-0.25 (-1.49%)

, SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

18:51
11/13/19
11/13
18:51
11/13/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ping…

PING

Ping Identity

$16.50

-0.25 (-1.49%)

SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

PRSP

Perspecta

$27.79

-0.18 (-0.64%)

HI

Hillenbrand

$31.53

-1 (-3.07%)

CPA

Copa Holdings

$107.71

1.89 (1.79%)

PSNL

Personalis

$10.92

0.745 (7.33%)

TRQ

Turquoise Hill

$0.46

-0.006 (-1.29%)

CATS

Catasys

$14.60

-0.47 (-3.12%)

LTRX

Lantronix

$3.15

0.06 (1.94%)

SLGG

Super League Gaming

$3.06

0.07 (2.34%)

BZH

Beazer Homes

$14.67

0.21 (1.45%)

CSCO

Cisco

$48.44

0.06 (0.12%)

TTEK

Tetra Tech

$88.38

1.24 (1.42%)

NTAP

NetApp

$60.04

-0.08 (-0.13%)

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 14

    Nov

BZH

Beazer Homes

$14.67

0.21 (1.45%)

18:49
11/13/19
11/13
18:49
11/13/19
18:49
Earnings
Beazer Homes reports Q4 EPS 8c, two estimates 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HT

Hersha Hospitality

$13.84

-0.23 (-1.63%)

18:46
11/13/19
11/13
18:46
11/13/19
18:46
Hot Stocks
Hersha Hospitality CEO: Airnb has definitely had an impact »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

FICO

Fair Isaac

$336.80

2.56 (0.77%)

18:40
11/13/19
11/13
18:40
11/13/19
18:40
Hot Stocks
Fair Isaac director sells 6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

18:33
11/13/19
11/13
18:33
11/13/19
18:33
Hot Stocks
ProPetro discloses U.S. SEC probe »

ProPetro has filed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

DXCM

DexCom

$202.81

-3.35 (-1.63%)

, WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

18:25
11/13/19
11/13
18:25
11/13/19
18:25
Hot Stocks
DexCom CEO: The type 2 diabetes business is just getting started »

In an interview on…

DXCM

DexCom

$202.81

-3.35 (-1.63%)

WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 22

    Nov

EQS

Equus II Inc

$1.55

(0.00%)

18:19
11/13/19
11/13
18:19
11/13/19
18:19
Hot Stocks
Equus reports Q3 NAV per share of $3.63 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSYS

Stratasys

$18.35

-2.39 (-11.52%)

18:04
11/13/19
11/13
18:04
11/13/19
18:04
Recommendations
Stratasys analyst commentary at Piper Jaffray »

Stratasys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GLD

SPDR Gold Shares

$137.98

0.56 (0.41%)

18:03
11/13/19
11/13
18:03
11/13/19
18:03
Hot Stocks
SPDR Gold Shares holdings fall to 896.77MT from 897.09MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

17:57
11/13/19
11/13
17:57
11/13/19
17:57
Hot Stocks
Copa Holdings reports October capacity down 4.8%, traffic down 1.4% »

Copa Holdings released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

CCI

Crown Castle

$131.34

0.67 (0.51%)

17:51
11/13/19
11/13
17:51
11/13/19
17:51
Hot Stocks
Crown Castle chairman buys 10.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

17:48
11/13/19
11/13
17:48
11/13/19
17:48
Periodicals
Google confirms several features not available on Stadia at launch, Kotaku says »

During an AMA on Reddit,…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.